Narcolepsy with cataplexy;Narcolepsie avec cataplexie

Revue Neurologique

Volumn 164, Issue 8-9, 2008, Pages 634-645

  Dauvilliers, Y ^a,b,c   Arnulf, I ^c,d,e  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b Montpellier 1 University   (France)

^c Centre de référence nationale maladie rare narcolepsie et hypersomnie idiopathique   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Autoimmune; Genetic; HLA; Hypocretin; Narcolepsy; Sleepiness

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HISTAMINE; HISTAMINE H3 RECEPTOR ANTAGONIST; HLA ANTIGEN; HLA DQB1 ANTIGEN; IMMUNOGLOBULIN; MAZINDOL; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CATAPLEXY; CEREBROSPINAL FLUID LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; DAYTIME SOMNOLENCE; DECREASED APPETITE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENURESIS; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HLA TYPING; HUMAN; HYPERTENSION; HYPNAGOGIC HALLUCINATION; INSOMNIA; IRRITABILITY; MOTOR DYSFUNCTION; NARCOLEPSY; NERVOUSNESS; NONHUMAN; PAIN; PARALYSIS; PARASOMNIA; POLYSOMNOGRAPHY; PREVALENCE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REM SLEEP; REVIEW; SIDE EFFECT; SLEEP DISORDER; SLEEP WALKING; SYMPTOM; TACHYCARDIA; VERTIGO; WEIGHT GAIN; DIFFERENTIAL DIAGNOSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES;

EID: 58149122923     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2007.08.012     Document Type: Review

References (80)

1. American Academy of Sleep Medicine. The international Classification of Sleep Disorders - Revised (2005), American Academy of Sleep Medicine, Chicago
2. Alvarez B., Dahlitz M., Grimshaw J., and Parkes J.D. Mazindol in long-term treatment of narcolepsy. Lancet 337 (1991) 1293-1294
3. Arnulf I., Konofal E., Merino-Andreu M., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58 (2002) 1019-1024
4. Arnulf I., Zeitzer J.M., File J., Farber N., and Mignot E. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 128 (2005) 2763-2776
5. Auger R.R., Goodman S.H., Silber M.H., Krahn L.E., Pankratz V.S., and Slocumb N.L. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 28 (2005) 667-672
6. Baumann C.R., and Bassetti C.L. Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol 4 (2005) 673-682
7. Billiard M., and Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 5 (2001) 349-358
8. Billiard M., Bassetti C., Dauvilliers Y., et al., EFNS Task Force. EFNS guidelines on management of narcolepsy. Eur J Neurol 13 (2006) 1035-1048
9. Black III J.L., Silber M.H., Krahn L.E., et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 28 (2005) 427-431
10. Black J., Houghton W., and Xyrem® International Study Group. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29 (2006) 939-946
11. Blouin A.M., Thannickal T.C., Worley P.F., et al. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65 (2005) 1189-1192
12. Broughton R., Ghanem Q., Hishikawa Y., Sugita Y., Nevsimalova S., and Roth B. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci 8 (1981) 299-304
13. Carskadon M.A., Mitler M.M., and Roth T. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep 9 (1986) 519-524
14. Chemelli R.M., Willie J.T., Sinton C.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
15. Crocker A., Espana R.A., Papadopoulou M., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65 (2005) 1184-1188
16. Daniels E., King M.A., Smith I.E., and Shneerson J.M. Health-related quality of life in narcolepsy. J Sleep Res 10 (2001) 75-81
17. Dauvilliers Y., Montplaisir J., Molinari N., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57 (2001) 2029-2033
18. Dauvilliers Y., Neidhart E., Lecendreux M., Billiard M., and Tafti M. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 6 (2001) 367-372
19. Dauvilliers Y., Neidhart E., Billiard M., and Tafti M. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J 2 (2002) 65-68
20. Dauvilliers Y., Carlander B., Molinari N., et al. Month of birth as a risk factor for narcolepsy. Sleep 26 (2003) 663-665
21. Dauvilliers Y., Billiard M., and Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 114 (2003) 2000-2017
22. Dauvilliers Y., Baumann C.R., Carlander B., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74 (2003) 1667-1673
23. Dauvilliers Y., Blouin J.L., Neidhart E., et al. A narcolepsy susceptibility locus maps to a 5 Mb region of chromosome 21q. Ann Neurol 56 (2004) 382-388
24. Dauvilliers Y., Gosselin A., Paquet J., Touchon J., Billiard M., and Montplaisir J. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 62 (2004) 46-50
25. Dauvilliers Y., Carlander B., Rivier F., Touchon J., and Tafti M. Successful management of cataplexy with intravenous immunoglobulins shortly after narcolepsy onset. Ann Neurol 56 (2004) 905-908
26. Dauvilliers Y., Maret S., Bassetti C., et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 62 (2004) 2137-2138
27. Dauvilliers Y., and Tafti M. Molecular genetics and treatment of narcolepsy. Ann Med 38 (2006) 252-262
28. Dauvilliers Y. Differential diagnosis in hypersomnia. Curr Opin Neurol Neurosci 6 (2006) 156-162
29. Dauvilliers Y., Arnulf I., and Mignot E. Narcolepsy with cataplexy. Lancet 369 (2007) 499-511
30. Dauvilliers Y., Pennestri M.H., Petit D., Dang Vu T., and Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 16 (2007) 333-339
31. de Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95 (1998) 322-327
32. Findley L., Unverzagt M., Guchu R., Fabrizio M., Buckner J., and Suratt P. Vigilance and automobile accidents in patients with sleep apnea or narcolepsy. Chest 108 (1995) 619-624
33. Fronczek R., Overeem S., Lee S.Y., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130 (2007) 1577-1585
34. Gélineau J. De la narcolepsie. Gaz Hop (Paris) 53 (1880) 626-628
35. Gencik M., Dahmen N., Wieczorek S., Kasten M., Gencikova A., and Epplen J.T. ApoE polymorphisms in narcolepsy. BMC Med Genet 2 (2001) 9
36. Hara J., Beuckmann C.T., Nambu T., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001) 345-354
37. Hohjoh H., Nakayama T., Ohashi J., et al. Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 54 (1999) 138-145
38. Hublin C., Kaprio J., Partinen M., et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 35 (1994) 709-716
39. Juji T., Satake M., Honda Y., and Doi Y. HLA antigens in Japanese patients with narcolepsy. Tissue Antigens 24 (1984) 316-319
40. Kotagal S., Krahn L.E., and Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 5 (2004) 147-150
41. Lammers G.J., Arends J., Declerck A.C., Ferrari M.D., Schouwink G., and Troost J. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16 (1993) 216-220
42. Langdon N., Shindler J., Parkes J.D., and Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 9 (1986) 371-373
43. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
44. Mieda M., Willie J.T., Hara J., et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 101 (2004) 4649-4654
45. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 (1998) S16-S22
46. Mignot E., Lin L., Rogers W., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68 (2001) 686-699
47. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnostic of narcolepsy and other hypersomnias. Arch Neurol 59 (2002) 1553-1562
48. Mignot E., and Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 28 (2005) 754-763
49. Mignot E., Lin L., Finn L., et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 129 (2006) 1609-1623
50. Mileykovskiy B.Y., Kiyashchenko L.I., and Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46 (2005) 787-798
51. Mitler M.M., Shafor R., Hajdukovich R., Timms R.M., and Browman C.P. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 9 (1986) 260-264
52. Nakayama J., Miura M., Honda M., Miki T., Honda Y., and Arinami T. Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 65 (2000) 84-86
53. Nightingale S., Orgill J.C., Ebrahim I.O., de Lacy S.F., Agrawal S., and Williams A.J. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med. 6 (2005) 253-258
54. Nishino S., and Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 9 (2005) 269-310
55. Ohayon M.M. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 97 (2000) 153-164
56. Ohayon M.M., Priest R.G., Zulley J., Smirne S., and Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 58 (2002) 1826-1833
57. Overeem S., Reijntjes R., Huyser W., Lammers G.J., and van Dijk J.G. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. J Sleep Res 13 (2004) 257-264
58. Overeem S., Verschuuren J.J., Fronczek R., et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol 174 (2006) 187-191
59. Parkes D., and Schachter M. Clomipramine and and clonazepam in narcolepsy. Lancet 2 (1979) 1085-1086
60. Pelin Z, Guilleminault C, Risch N, Grumet FC, Mignot E. (1998), HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens, 51: 96-100.
61. Peyron C., Tighe D.K., van den Pol A.N., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18 (1998) 9996-10015
62. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brain. Nat Med 6 (2000) 991-997
63. Picchioni D., Mignot E.J., and Harsh J.R. The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602. Sleep 27 (2004) 1471-1475
64. Ripley B., Fujiki N., Okura M., Mignot E., and Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 8 (2001) 525-534
65. Roth B., and Nevsimalova S. Depression in narcolepsy and hypersommia. Schweiz Arch Neurol Neurochir Psychiatry 116 (1975) 291-300
66. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
67. Saper C.B., and Scammell T.E. Modafinil: a drug in search of a mechanism. Sleep 27 (2004) 11-12
68. Siebold C., Hansen B.E., Wyer J.R., et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci U S A 101 (2004) 1999-2004
69. Smith M., Parkes J., and Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 5 (1996) 217
70. Thannickal T.C., Moore R.Y., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
71. Thannickal T.C., Lai Y.Y., and Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007) 1586-1595
72. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 43 (1998) 88-97
73. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 54 (2000) 1166-1175
74. US Xyrem Multicenter Study group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 5 (2004) 119-123
75. US Xyrem Multicenter Study group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25 (2002) 42-49
76. Vgontzas A.N., Bixler E.O., Kales A., Criley C., and Vela-Bueno A. Differences in nocturnal and daytime sleep between primary and psychiatric hypersomnia: diagnostic and treatment implications. Psychosom Med 62 (2000) 220-226
77. Westphal C. Eigentümliche mit Einschlafen Verbundene Anfälle. Arch Psychiatr Nervenkr 7 (1877) 631-635
78. Wieczorek S., Jagiello P., Arning L., Dahmen N., and Epplen J.T. Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA. J Mol Med 82 (2004) 696-705
79. Willie J.T., Chemelli R.M., and Sinton C.M. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38 (2003) 715-730
80. Young T., Palta M., Dempsey J., Skatrud J., Weber S., and Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328 (1993) 1230-1235